ESMB has entered archive mode. All posts and threads that were available to the general public are still readable. The board is still searchable. 

Thank you all for your participation and readership over the last 12 years.

If you want to join in the conversation, please join the new ESMB Redux at www.exscn2.net.



Yet another Scilon with cancer asking for donations on GoFundMe..

Discussion in 'General Scientology Discussion' started by Smurf, Jun 22, 2015.

View Users: View Users
  1. Gizmo

    Gizmo Rabble Rouser

    In the US it is more complicated than " funded ".

    The US Gov't already runs a health care system called the VA ( Veterans Administration ) & it is dysfunctional.

    Meficare ? Frought with fraud.

    Obama Care - all 2500 ill defined pages ? Without a single word about TORT REFORM ?

    The US Gov't has yet to figure out how to do much besides make politicians into millionaires.

    Yes, the US needs healthcare somewhat sanely implemented .
     
  2. Cat's Squirrel

    Cat's Squirrel Gold Meritorious Patron

    In what way?
     
  3. Gizmo

    Gizmo Rabble Rouser

    Pretty plain I thought ...
     
  4. Udarnik

    Udarnik Gold Meritorious Patron

    I have no Internet and cell service is spotty out here (plus no one speaks English), so I'll deviate from my normal MO and keep this short :lol:.

    No matter where you do the trials, the Treaty of Helsinki applies. There is a shift to 2nd world countries, due to the fact that any have not had access to "gold standard" drugs in the 1st world, and many trial designers work better in naive patients. You can't do trials in thev3rd world because the shitty healthcare in everything you are not studying confounds he results. I worked on a drug tested in India, and a patient died because they had minor outpatient surgery, the surgeon FORGOT TO TAKE OUT THE GAUZE, that parent aspirated the gauze and choked to death. obviously not drug related, but also obviously, that patent was lost to follow up.

    More later when I get back to civilization.
     
  5. degraded being

    degraded being Sponsor

    Thanks. Will forego provocative questions about how patients in 2nd world countries will be naive, but presumably those who are researcher's assistants, and even doctors, are not naive. Will also forego questions about....never mind.
    Yes, I can imagine the horrors of having to do serious research in some places, even the purely admin aspects of it would be enough to drive a person loopy!
    Good luck to you.
     
  6. Udarnik

    Udarnik Gold Meritorious Patron

    Are you being deliberately funny, or did you misunderstand what I meant by "naive"?

    In medicine, a patient is naive to something if they've never been exposed to it: a drug, a virus, whatever.

    In the 2nd world, a lot of patients are not given what's gold standard in the West because it costs too much, but otherwise their healthcare is pretty cromulent - in general their surgeons don't leave their tools in them after an operation. And if they get TB, they get isoniazid and rifampin and get better. But they won't get, for example, Enbrel for their Rheumatoid Arthritis, they'll get methorexate and steroids, and maybe leflunomide on top of that if they fail that regimen.

    Those patients will enter an Enbrel trial because their current regimen isn't working all that well, and the trial gives them access to Enbrel, which they otherwise would never get, or get only after a lengthy waiting period in their country. Meanwhile, the drug company gets an Enbrel-naive patient, in fact a fair amount of them. To find such a patient in the US would mean recruiting them right at the exact time their doc decides "enough is enough" on methotrexate. It's really hard to find enough sites with enough of those kind of patients who are switching right during the 18 month time window of a clinical trial recruiting period (and of those eligible, not all will volunteer for the trial...). The 2nd world option is a win-win-win for the 2nd world patient, the Pharma company AND the first world regulators who want to see how the new drug really performs in a naive population.